Bicara's Ficerafusp Alfa Doubles Survival in HPV-Negative HNSCC

Event summary

  • Ficerafusp alfa plus pembrolizumab achieved a 31% three-year overall survival rate in 1L R/M HPV-negative HNSCC, doubling standard-of-care outcomes.
  • Deep responses (≥80% tumor shrinkage) were observed in 77-80% of responders at higher doses, correlating with durable long-term outcomes.
  • Bicara plans to initiate a 12-week loading dose study in Q3 2026 to support long-term administration.
  • Data will be presented at ASCO 2026, with a conference call scheduled for May 22, 2026.

The big picture

Bicara's data reinforces the potential of TGF-β inhibition in overcoming tumor resistance, a critical challenge in solid tumor treatments. The results position ficerafusp alfa as a differentiated therapy in a head and neck cancer market with limited durable options for HPV-negative patients. Success in the Phase 3 trial could reshape the treatment landscape, particularly if the survival benefits are replicated in larger cohorts.

What we're watching

Clinical Validation
Whether the deep response and survival data will position ficerafusp alfa as a best-in-class therapy for HPV-negative HNSCC.
Regulatory Pathway
The pace at which Bicara advances the FORTIFI-HN01 pivotal trial and secures FDA approval for ficerafusp alfa.
Dosing Optimization
How the planned loading dose study impacts long-term administration and commercial viability.